ValuEngine upgraded shares of Catalent (NYSE:CTLT) from a hold rating to a buy rating in a research report sent to investors on Tuesday.
Other research analysts also recently issued research reports about the stock. Zacks Investment Research raised shares of Catalent from a hold rating to a buy rating and set a $46.00 price objective on the stock in a research report on Thursday, March 8th. Raymond James raised shares of Catalent from a market perform rating to an outperform rating and set a $48.00 price objective on the stock in a research report on Wednesday, March 21st. They noted that the move was a valuation call. UBS Group raised shares of Catalent from a market perform rating to an outperform rating in a research report on Wednesday, March 21st. Finally, KeyCorp raised shares of Catalent from a sector weight rating to an overweight rating and set a $48.00 price objective on the stock in a research report on Wednesday, March 28th. Five research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The company has an average rating of Buy and a consensus target price of $45.67.
Shares of CTLT stock opened at $41.26 on Tuesday. The company has a debt-to-equity ratio of 2.53, a quick ratio of 1.78 and a current ratio of 2.18. Catalent has a 12-month low of $33.42 and a 12-month high of $47.87. The company has a market capitalization of $5.48 billion, a P/E ratio of 30.56, a P/E/G ratio of 2.00 and a beta of 1.50.
Catalent (NYSE:CTLT) last issued its quarterly earnings data on Tuesday, May 1st. The company reported $0.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.35 by $0.06. Catalent had a net margin of 2.62% and a return on equity of 21.76%. The firm had revenue of $627.90 million for the quarter, compared to the consensus estimate of $610.47 million. During the same quarter in the previous year, the firm earned $0.38 EPS. The company’s quarterly revenue was up 17.9% compared to the same quarter last year. equities analysts predict that Catalent will post 1.55 EPS for the current year.
In other Catalent news, SVP Steven L. Fasman sold 2,252 shares of the business’s stock in a transaction that occurred on Wednesday, June 20th. The shares were sold at an average price of $41.78, for a total transaction of $94,088.56. The transaction was disclosed in a filing with the SEC, which is available at this link. 1.70% of the stock is currently owned by insiders.
A number of large investors have recently added to or reduced their stakes in CTLT. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp purchased a new stake in shares of Catalent in the 4th quarter valued at $242,000. California Public Employees Retirement System boosted its holdings in shares of Catalent by 4.1% in the 4th quarter. California Public Employees Retirement System now owns 220,285 shares of the company’s stock valued at $9,049,000 after acquiring an additional 8,673 shares during the last quarter. Municipal Employees Retirement System of Michigan boosted its holdings in shares of Catalent by 5.1% in the 4th quarter. Municipal Employees Retirement System of Michigan now owns 39,730 shares of the company’s stock valued at $1,632,000 after acquiring an additional 1,940 shares during the last quarter. First Trust Advisors LP boosted its holdings in shares of Catalent by 95.6% in the 4th quarter. First Trust Advisors LP now owns 214,784 shares of the company’s stock valued at $8,823,000 after acquiring an additional 104,969 shares during the last quarter. Finally, Carillon Tower Advisers Inc. purchased a new stake in shares of Catalent in the 4th quarter valued at $27,561,000. 99.34% of the stock is currently owned by institutional investors.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through three segments: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. The Softgel Technologies segment offers formulation, development, and manufacturing services for softgels, which are used in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, and unit-dose cosmetics.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.